Free Trial
NASDAQ:SMLR

Semler Scientific Q3 2025 Earnings Report

Semler Scientific logo
$30.56 -0.80 (-2.55%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$31.16 +0.61 (+1.98%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Semler Scientific EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Semler Scientific Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.87 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Semler Scientific Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Monday, November 3, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Semler Scientific? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Semler Scientific and other key companies, straight to your email.

About Semler Scientific

Semler Scientific (NASDAQ:SMLR), Inc., headquartered in Princeton, New Jersey, is a medical technology company specializing in the development and commercialization of non-invasive monitoring solutions for intracranial pressure. The company’s core focus is on improving patient care in neurocritical and acute care settings by providing clinicians with advanced diagnostic tools that reduce the risks associated with invasive procedures.

The company’s flagship product, the NICO Monitor, employs proprietary acoustic monitoring technology to continuously estimate intracranial pressure and compliance at the bedside. By placing a small, ear-canal sensor on the patient, the system captures and analyzes low-frequency sound waves generated within the skull, offering real-time insights without the need for surgical implantation of pressure sensors. This non-invasive approach is designed to support faster clinical decision-making and may help reduce complications linked to invasive intracranial monitoring techniques.

Since its founding in the mid-2000s, Semler Scientific has secured regulatory clearances, including FDA 510(k) approval for use in the United States, and has worked with leading hospitals and health systems to integrate its technology into neurocritical care protocols. The company continues to collaborate with clinical investigators and pursue additional regulatory pathways to broaden the use of its monitoring platform across other patient populations and geographies.

Led by a management team with backgrounds in biomedical engineering, neurosurgery and commercial strategy, Semler Scientific emphasizes innovation in point-of-care monitoring. Its leadership continues to engage with clinicians, researchers and strategic partners to expand the clinical utility and adoption of its non-invasive intracranial pressure monitoring solutions worldwide.

View Semler Scientific Profile

More Earnings Resources from MarketBeat